Ascentage Pharma
AAPG
14 hedge funds and large institutions have $3.69M invested in Ascentage Pharma in 2025 Q3 according to their latest regulatory filings, with 6 funds opening new positions, 3 increasing their positions, 4 reducing their positions, and 4 closing their positions.
50% more first-time investments, than exits
New positions opened: 6 | Existing positions closed: 4
17% more funds holding
Funds holding: 12 → 14 (+2)
14% more capital invested
Capital invested by funds: $3.22M → $3.69M (+$466K)
0.01% more ownership
Funds ownership: 0.09% → 0.1% (+0.01%)
25% less repeat investments, than reductions
Existing positions increased: 3 | Existing positions reduced: 4
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
XC
XY Capital
Central,
Hong Kong
|
+$507K |
| 2 |
UBS Group
Zurich,
Switzerland
|
+$445K |
| 3 |
Citadel Advisors
Miami,
Florida
|
+$391K |
| 4 |
AA
ABC Arbitrage
Paris,
France
|
+$212K |
| 5 |
Mirae Asset Global Investments
Seoul,
South Korea
|
+$99.7K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
HSBC Holdings
London,
United Kingdom
|
-$391K |
| 2 |
Chevy Chase Trust
Bethesda,
Maryland
|
-$227K |
| 3 |
NIM
NEOS Investment Management
Westport,
Connecticut
|
-$207K |
| 4 |
TE
Tema ETFs
New York
|
-$207K |
| 5 |
PD
Point72 (DIFC)
Dubai,
United Arab Emirates
|
-$120K |
AAPG Hedge Fund Activity: Q3 2025 in Review
14 of the 7,641 institutional investors tracked by Wall St. Rank reported a position in Ascentage Pharma (AAPG) for Q3 2025, worth a combined $3.69M — up 14% from $3.22M a quarter earlier.
Buyers outnumbered sellers: 6 funds opened new AAPG positions and 4 closed out — a net gain of 2 holders — while 3 added to existing stakes and 4 trimmed.
The largest buyer was XY Capital, adding an estimated $507K. The largest seller was HSBC Holdings, exiting entirely with an estimated $391K sold.
- 14 institutional investors held Ascentage Pharma (AAPG) as of Q3 2025, up from 12 in Q2 2025.
- Funds reported $3.69M of Ascentage Pharma stock for Q3 2025, up 14% quarter-over-quarter.
- 6 funds opened new Ascentage Pharma positions in Q3 2025 and 4 closed out, a net change of +2 holders.
- The largest Ascentage Pharma buyer in Q3 2025 was XY Capital, an estimated $507K added.
- The largest Ascentage Pharma seller in Q3 2025 was HSBC Holdings, an estimated $391K sold.
Based on aggregated 13F filings for Q3 2025.